Arteris director granted 4,703 RSUs

Arteris, Inc. director Joachim Kunkel received an equity grant of 4,703 shares of common stock in the form of restricted stock units (RSUs) as board compensation.

Rhea-AI Filing Summary

Arteris, Inc. director Joachim Kunkel received an equity grant of 4,703 shares of common stock in the form of restricted stock units (RSUs) as board compensation. The award carried no cash exercise price and increased his directly held position to 74,330 shares.

The 4,703 RSUs each represent a contingent right to one share of common stock and will vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, as long as he continues serving on the board. The grant was based on the average trading price of Arteris stock of $31.89 over the April 21, 2026 to June 2, 2026 period, and Kunkel elected to defer receipt of the shares.

Insider Trade Summary

Grant/Award: 4,703 shares

Grant/Award 1 txn

Insider Kunkel Joachim

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,703	$0.00	$0.00

Holdings After Transaction: Common Stock — 74,330 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person elected to defer the receipt of shares.
2. F2. Includes 4,703 restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the annual meeting of the Issuer's stockholders following the grant date, subject to the reporting person continuing to provide services to Issuer's Board through such vesting date. The RSUs have no expiration date. This grant of restricted stock was made on June 2, 2026, based on the average trading price of Arteris, Inc. common stock for the period from April 21, 2026 through June 2, 2026, which was $31.89.

Key Figures

RSU grant size: 4,703 RSUs Shares held after transaction: 74,330 shares Average trading price: $31.89

3 metrics

RSU grant size 4,703 RSUs Director equity award on June 2, 2026

Shares held after transaction 74,330 shares Direct holdings following RSU grant

Average trading price $31.89 Average Arteris stock price from April 21, 2026 to June 2, 2026 used to size grant

Key Terms

restricted stock units ("RSUs"), contingent right, annual meeting of the Issuer's stockholders, vest in full

4 terms

restricted stock units ("RSUs") financial

"Includes 4,703 restricted stock units ("RSUs"), each of which represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"each of which represents a contingent right to receive one share of the Issuer's common stock"

annual meeting of the Issuer's stockholders financial

"immediately before the annual meeting of the Issuer's stockholders following the grant date"

vest in full financial

"The RSUs will vest in full on the earlier of (i) the first anniversary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arteris (AIP) director Joachim Kunkel report?

Arteris director Joachim Kunkel reported an award of 4,703 restricted stock units. Each RSU represents a contingent right to one share of common stock, granted as board compensation and subject to time-based vesting tied to continued service on the company’s board.

How many Arteris (AIP) shares does Joachim Kunkel hold after this Form 4?

After the reported grant, Joachim Kunkel holds 74,330 Arteris common shares directly. This total includes 4,703 restricted stock units that convert to shares upon vesting, assuming he continues providing services to Arteris’ board through the applicable vesting date.

What are the vesting terms of Joachim Kunkel’s 4,703 Arteris (AIP) RSUs?

The 4,703 RSUs vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, provided Kunkel continues serving on Arteris’ board through that vesting date, with no stated expiration.

How was the size of Joachim Kunkel’s Arteris (AIP) RSU grant determined?

The RSU grant size was based on the average trading price of Arteris common stock of $31.89 for the period from April 21, 2026 through June 2, 2026. This price was used to calculate the number of RSUs awarded as equity compensation.

Did Joachim Kunkel pay a price per share for the Arteris (AIP) RSU award?

No, the Form 4 shows a transaction price per share of $0.00 for the 4,703 RSUs. This indicates the award was granted as compensation, rather than purchased in the open market, consistent with typical director equity grants at public companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 07:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kunkel Joachim

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CALIFORNIA 95008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		A		4,703(1)(2)	A	$0.00	74,330	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person elected to defer the receipt of shares.

2. Includes 4,703 restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the annual meeting of the Issuer's stockholders following the grant date, subject to the reporting person continuing to provide services to Issuer's Board through such vesting date. The RSUs have no expiration date. This grant of restricted stock was made on June 2, 2026, based on the average trading price of Arteris, Inc. common stock for the period from April 21, 2026 through June 2, 2026, which was $31.89.

Remarks:

	/s/ Paul Alpern as Attorney-in-fact for Joachim Kunkel	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)